CTT PHARMACEUTICAL HOLDINGS, INC. purchased $147 of CTTH
CTT PHARMACEUTICAL HOLDINGS, INC. (CEO) purchased 3,000 shares of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) at $0.05 on 2026-09-02.
How this was made
The 30-second read
Why it matters
The CEO's modest purchase adds marginal confidence but is unlikely to move the stock materially.
Market read
Primary insider filing with low material impact; relevant mainly to traders tracking micro‑cap insider activity.
What to watch
Potential upcoming corporate actions or financing needs not disclosed.
Background
Form 4 filings disclose insider transactions and are used to gauge insider sentiment.
Ticker impact
CEO purchased 3,000 shares for $146.70, increasing holdings to over 9.3 million shares.
Limited short‑term impact; may provide slight bullish bias.
Form 4 is a primary disclosure, but the dollar amount is trivial for a micro‑cap, so price reaction is likely muted.
Market effects
None significant for the broader pharmaceutical sector.
No notable regional effect.
Limited to micro‑cap investors.
Counterpoint
The purchase could be a routine portfolio rebalancing rather than a confidence signal.
Key entities
- CompanyCTT Pharmaceutical Holdings, Inc.
Micro‑cap pharmaceutical company reporting an insider purchase.